Clinical trials are research studies that test new potential treatments for a disease. Talk to your doctor about possible clinical trials that could be helpful to you.
*CHB=Chronic hepatitis B, HBD=hepatitis D
For trials listed as "International" or "International Only," click on the NCT identification number for a complete list of participating countries.
Treatment of Chronic Delta Hepatitis with Lonafarnib and Ritonavir – U.S.
Determine the safety and efficacy of Lonafarnib and Ritonavir for the treatment of patients with hepatitis D. Contact: Nancy Fryzek at firstname.lastname@example.org. Refer to identifier NCT02511431 (Study ID # 150170, 15-DK-0170)
Evaluation of Patients with Liver Disease, Including Hepatitis D – U.S.
Evaluate, investigate and follow-up patients suffering from acute and chronic liver disease. Qualified patients may be able to participate in other offered studies. Contact: Nancy Fryzek at 301-435-6122 email@example.com or Dr. T. Jake Liang at 301-496-1721 firstname.lastname@example.org. Refer to identifier NCT00001971 (Study ID # 910214, 91-DK-0214)
The Hepatitis Delta International Network –International
Multicenter, observational study will build a registry of HDV patients around the world and collect clinical information. Contact: Dr. Heiner Wedemeyer at Wedemeyer.Heiner@mh-hannover.de or Dr. SvenjaHardtke at Hardtke.Svenja@mh-hannover.de and refer to identifier NCT02375906 (Study ID # HepNet-HDIN)
Mother-to-Child Hepatitis D Transmission - France
Observational cohort to gather data on vertical transmission of HDV. Contact: Dr. Pierre Sellier at 00 33 149956339 email@example.com fefer to identifier NCT02044055 (Study ID # Liver004)
A Long Term Follow-up Study of Patients From the REP 301 Protocol - Moldova
This study extends the follow-up and monitoring of patients with hepatitis B/D coinfection who were treated in the REP 301 trial. Contact Dr. Victor Pantea at +373 69 37 11 27 or firstname.lastname@example.org and refer to identifier NCT02876419.
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection – New Zealand and Pakistan
This Phase II study determines if pegylated interferon lambda-1a is more effective and will cause fewer side effects than interferon alpha treatment in patients with hepatitis D. New Zealand: contact Isabel Gorham at 650-272-6138 or email@example.com and refer to identifier NCT02765802. Pakistan: contact Nimra Bader at firstname.lastname@example.org and refer to identifier NCT02765802.
Lonafarnib With Ritonavir in HDV (LOWR-2) (LOWR-2) – Turkey
This is an open-label, dose-rangingsudy to evaluate the safety and efficacy of Lonafarnibwith Ritonavir-boosting in patients chronically infected with hepatitis Delta. Contact Dr. Cihan Yurdaydinat Cihan.Yurdaydin@medicine.ankara.edu.tr and refer to study identifier NCT02430194.
Learn more about current HDV clinical trials.
www.clinicaltrials.gov is a service of the National Institutes of Health that provides a list of all the clinical trials that are being carried out in the United States. You can search for a clinical trial by disease, drug therapy, or trial location.
www.searchclinicaltrials.org offers a free search service by the Center for Information and Study on Clinical Research Participation (CISCRP) to help you find a clinical trial that may be right for you.
Hepatitis B Clinical Trials Page is a list that is updated each month by the Hepatitis B Foundation of clinical trials specific for hepatitis B.